Assessment of the Effects of Raloxifene on Salivary Estradiol and Progesterone Levels
Deviations from normal levels of serum E(2) and P are of interest in evaluating ovarian
function. However, the day-to-day variations in these levels necessitates serial blood
sampling or elaborate efforts to time blood draws within specific phases of the menstrual
cycle. A noninvasive method for assessment of the levels of sex steroids on a daily basis
using saliva has been developed. This study will assess the levels of estradiol and
progesterone during 3 menstrual cycles (pre-drug and after 3 and 12 months of raloxifene
therapy) in pre-menopausal women participating in a pilot chemoprevention trial of
raloxifene.
Interventional
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
United States: Federal Government
990180
NCT00026962
September 1999
August 2003
Name | Location |
---|---|
National Cancer Institute (NCI) | Bethesda, Maryland 20892 |